Spruce Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SPRB Nasdaq 2830 sprucebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spruce Biosciences, Inc.

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium - May 28th, 2026 2:05 pm
Spruce Biosciences to Participate in Upcoming Conferences in June - May 27th, 2026 2:05 pm
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - May 13th, 2026 6:00 am
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations - May 4th, 2026 6:00 am
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - Apr 20th, 2026 9:45 pm
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Apr 20th, 2026 2:01 pm
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - Apr 3rd, 2026 7:55 am
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect? - Mar 18th, 2026 7:55 am
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss - Mar 17th, 2026 5:59 pm
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - Mar 9th, 2026 5:05 am
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer - Mar 9th, 2026 5:00 am
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway - Mar 3rd, 2026 10:11 pm
Spruce Biosciences to Present at Upcoming Investor Conferences in March - Mar 2nd, 2026 2:05 pm
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference - Mar 1st, 2026 3:37 pm
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Feb 18th, 2026 5:00 am
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 17th, 2026 2:05 pm
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) - Feb 5th, 2026 2:05 pm
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - Feb 3rd, 2026 6:00 am
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - Jan 28th, 2026 6:00 am
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - Jan 18th, 2026 5:02 pm